AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05306691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).
Description: Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
Study NCT05306691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).
Description: Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
Study NCT05479825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inflation- deflation line combined with ICG fluorography
Description: Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
Study NCT05588661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation Exercises
Description: Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients.
Study NCT05588661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks
Study NCT05477264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.
Study NCT04993716 — intervention group
Intervention type: OTHER
Intervention: observational
Description: Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
Study NCT05135065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-Assisted Supervision Protocol
Description: Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
Study NCT06499870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06499870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT06499870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Piflufolastat
Description: Undergo fluorine F 18 piflufolastat PET/MRI
Study NCT06499870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT06499870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT06499870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT06499870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06499870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT04821050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Description: A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks.
Study NCT05869812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaHMB (Dietary supplement, not Drug)
Description: The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
Study NCT05869812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CaLa
Description: Comparative placebo
Study NCT06635421 — intervention group
Intervention type: OTHER
Intervention: Model of care delivery for long-acting injectable ART
Description: This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
Study NCT05004623 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sentinel Lymph Node Biopsy
Description: Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
Study NCT04821050 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks.
Study NCT05263388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REKOVELLE (Follitropin Delta)
Description: REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
Study NCT05263388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GONAL-F (Follitropin Alfa)
Description: GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
Study NCT06528860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight® 1 day soft contact lenses
Description: Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.
Study NCT06528860 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Proclear® 1 day soft contact lenses
Description: Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
Study NCT04535271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Study NCT05152979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verb Network Strengthening Treatment (VNeST)
Description: Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
Study NCT05152979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verb Network Strengthening Treatment (VNeST)
Description: Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
Study NCT06358482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oscillating toothbrush
Description: oscillating toothbrush
Study NCT05792410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Dalpiciclib Isethionate Tablets
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral
Study NCT05792410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Fulvestrant
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
Study NCT06358482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard manual toothbrush
Description: standard manual toothbrush
Study NCT05792410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Bevacizumab injection
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
Study NCT05079152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX+PPV23;COVAX+IIV4
Description: 1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
Study NCT05079152 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX only (1st and 2nd dose)
Description: 1st dose: COVAX only; 2nd dose: COVAX only
Study NCT05079152 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23 for the 1st dose and IIV4 for the 2nd dose
Description: 1st dose: PPV23 only; 2nd dose: IIV4 only
Study NCT05100394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Therapeutic laser therapy was applied.
Study NCT05100394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound + Moist Heat pack + Exercises
Description: Ultrasound therapy, a moist heat pack, and a home exercise program were given.
Study NCT05807048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
Study NCT05807048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Intervention Medication
Description: The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously
Study NCT05807048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Intervention Medication
Description: The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment.
Study NCT06538974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free exoskeleton
Description: During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
Study NCT03634488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea (20mg/kg/day)
Description: Treatment of severe malnutrition in children with SCA in northern Nigeria
Study NCT03634488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-use therapeutic food
Description: Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
Study NCT03634488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food
Description: Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
Study NCT06543017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
Study NCT06521606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary open reduction and internal fixation
Description: The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.
Study NCT06521606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary external fixator
Description: ). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
Study NCT05029518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
Study NCT04845750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rodeo Micro Mapping Catheter
Description: The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
Study NCT05459246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes).
Study NCT04857216 — intervention group
Intervention type: DEVICE
Intervention: Perfusion Index
Description: perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
Study NCT05741736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: five-days small group-based lifestyle modification program
Description: healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
Study NCT06102967 — intervention group
Intervention type: BEHAVIORAL
Intervention: delirium
Description: Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
Study NCT06538363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Personalized training advice
Study NCT06538363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Education
Description: Generic training advice
Study NCT04972136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Bilateral Theta Burst Stimulation
Description: A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
Study NCT04972136 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bilateral Theta Burst Stimulation
Description: A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
Study NCT05180344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
Study NCT05665218 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: right heart catheterization
Description: Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.